Antineoplastic

Antineoplastics
Tabine series
2-Deoxy-D-ribose [intermediate]
2-Fluoroadenosine [HOT] [intermediate]
Zomib series
(R)-BoroLeu-(+)-Pinanediol-CF3COOH [HOT] [intermediate]

 

 

 

 

 

Streptozocin,18883-66-4
Streptozocin
Streptozocin,18883-66-4
CAS
18883-66-4
Molecular Formula
C8H15N3O7
Molecular Weight
265.2205
Systematic Name
Glucopyranose, 2-deoxy-2-(3-methyl-3-nitrosoureido)-, D-
Assay
99%, a-isomer:75%
Certificate of analysis
Streptozocin,18883-66-4
View via PDF file
Streptozocin,18883-66-4
Specification
Appearance
Pale yellow crystalline powder
Complies
Solubility
Soluble in water
Complies
Identification
UV Absorption
The UV absorption of 0.001% solution
in water exhibits a maximum at about
228nm
Complies
IR Spectrum
IR Spectrum in potassium bromide
dispersion of sample should be
concordant with that of
working standard spectrum
Complies
HPLC
Retention time of the sample should be
concordant to the retention time of
workingstandard
Complies
Element Analysis
Carbon, Nitrogen, Hydrogen
Complies
Melting point
121°C(DEC)
121°C(DEC)
[α]D(c=1,H2O)
+39°
+39°
α Isomer%
≥75%
85%
Residue On Ignition
NMT 0.1%
0.02%
Heavy metals
Max 20ppm
Complies
Loss On Drying
NMT 1.0%
0.33%
Single Impurity
NMT 0.5%
0.1%
Total Impurity
NMT 1.0%
0.2%
Assay
99%
99.5%
Contact us for more information
Chemical information
Compound Name*
CAS No. "N/A" if the CAS not available*
Quantity*
Contact information
Contact person*
Email Address *
Tel No.*
Company or Organization Name*
Shipping Address*
Country
Remarks

<Privacy policy: the contact information will be only used for this business contact>

Related Antineoplastic Antibiotics
   
Patent Disclaimer
PD1
Products protected by valid patents are not offered for sale in jurisdictions where the sale of such products constitutes a patent infringement. The current list only reflects the products and technologies that are available, under development: note that some products may be developed or produced for internal and experimental uses with no commercal aim.
PD2
Sales of products are limited to those allowed by Chapter VII PLPRC 63, the above includes Research and development quantities.
PD3
the buyer assumes responsibility of all patent considerations in the use of
Lano ’s Pharmaceutical Co.,Ltd product(Streptozocin,18883-66-4).
PD4
R&D use in accordance with (1) 35 USC 271(e)+A13(1) in the U.S.; (2) Section 69.1 of Japanese Patent Law in Japan; (3) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (4) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (5) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (6) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (7) such similar laws and rules as may apply in various other countries.